First studies underway at Mayday University Hospital!

Posted:
16
June 2005

We are delighted to have started conducting clinical trials within Mayday University Hospital's flagship facilities. Construction and development of the new purpose built units was completed in May, allowing Early Phase studies to commence and complement our other premises within St George's University London.

“We moved into our new premises in early May and we are now conducting clinical research within the Mayday units. The transition has been very smooth and we are already reaping the rewards of the enhanced set-up.”— Dr Jörg Täubel, Managing Director, Richmond Pharmacology.
“Running clinical trials in our Mayday unit is proving very advantageous. The additional capacity we can manage up to 100 in-patients simultaneously. Our facilities are designed specifically for client and panel requirements and this helps trial conduct to run efficiently. For example, we now have dedicated monitoring facilities on the ward, with adjoining offices for a variety of support functions. I'm looking forward to taking full advantage of these facilities.”— Jean Van Wyk, Senior Research Physician and Head of Medical Department.
“The facilities have been purpose built, and this provides a tremendous advantage for our volunteers. The wards and recreational areas are spacious and comfortable. Volunteer feedback on the internet and lounge rooms has been very favourable. And, of course, it's reassuring to work within the acute environment of the NHS Trust.”— Dr Ulrike Lorch, Medical Director.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more